News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

Al's Comment:

 Very exciting trial. DNX-2401 is an oncolytic virus that had some success alone with GBMs - they reportedly even had 3 complete responses (out of 37 patients). At last report, these 3 patients are still alive and have no evidence of disease 3.2, 2, and 1.75 years after treatment - See details at: http://www.onclive.com/conference-coverage/sno-2014/Oncolytic-Virus-Shows-Early-Promise-in-Glioma#sthash.CQvVJ6Pr.dpuf  This used to be called Delta-24-RGD-4C.

Keytruda is a checkpoint inhibitor which has the potential to reverse the immune inhibition that GBMs have.  Combining these 2 treatments might make a major breakthrough. When the oncolytic virus kills a tumor cell, the Keytruda might allow the body's immune system to recognize and learn from the dead gbm cells and to kill the living GBM cells.

 


Posted on: 10/04/2015

 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740